sinphar pharmaceutical co.,ltd investor conference · indication total market value/year pancreatic...
Post on 25-Jun-2020
0 Views
Preview:
TRANSCRIPT
SINPHAR PHARMACEUTICAL CO.,LTDInvestor Conference
2018/11/05
SINPHAR’s Code :1734
SynCore’s Code :4192
免責聲明
◼ 本簡報是建立於本公司從各項來源所取得之資訊。有些資訊可能受未來不確定性因素影響,致使與原先本公司對於未來前景的說明迥異。未來若有變更或調整時,請以公開資訊觀測站公告資訊為依據。
◼ This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cause actual results to differ materially from those statements. Therefore, please refer to the information on MOPS website as the main basis if any adjustment has been made. (http://mops.twse.com.tw/mops/web/index)
Index
3
1. Brief intro of Group2. Operation of Group3. Main project and
strategy in 20194. Grate Health Map5. Social Responsibility
Born in Taiwan, Step forward to World
4
1977
Established Sinphar
Ilan, Taiwan
Generic、functional food、cosmetic
1997
Established CanCap
Vancouver, Canada
Clinical control for New Drug of North America、spot of international business
2008
Co-found SynCoreBio
Ilan, Taiwan
New Drug Development
2002
Invested Sinphar TianLi, He-Tian Tianli
Hangzhou (CN)、Xinjiang(CN)
Generic、TCM、Natural Resources
2012
Merged ZuniMed Biotech
Nantou,TW
Medical facilities
2002
R&D center
Ilan, Taiwan
Various laboratories, Chinese medicine, microorganisms, and cellular and molecular
biochemical functions
EPS and Dividends
5
Despite market condition and whether have New Drug
Investment, have earned shares and dividends annually.
。
1.1
0.6
0.8 0.8
0.9
1.15
1.3
0.5
0.64
0.33
0.90
0.65
0.35
0.6
1.6
0.8
0.6
0.1
0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0.00
0.50
1.00
1.50
2.00
2.50
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
EPS
股利
Recent group revenue
6
Term 2016 2017 2016 Q1-Q3 2017 Q1-Q3 2018 Q1-Q3
Therapeutic
drug1,481,598 1,470,125 1,071,321 1,071,522
Functional
Foods589,777 591,760 419,824 440,019
Others 62,136 72,278 48,964 54,170
Total 2,133,511 2,134,163 1,540,109 1,565,711 1,617,574
1,500,000
1,520,000
1,540,000
1,560,000
1,580,000
1,600,000
1,620,000
1,640,000
2016Q1-Q3 2017Q1-Q3 2018Q1-Q3
Revenue
NTD in Thousand
Profit and Loss in Recent
7
Term 2018Q2 2017Q2 2017 2016
Revenue 1,089,466 1,032,077 2,134,163 2,133,511
Gross Profit 37% 37% 38% 37%
S&M 160,971 137,893 280,681 319,519
G&A 118,332 110,119 229,112 229,947
R&D 160,396 181,607 363,493 382,605
Profit before Tax -41,412 -65,012 -90,166 -64,173
Net income (loss)
attributable to:
shareholders of
the parent
15,429 482 36,726 16,545
EPS(Basic) 0.09 - 0.22 0.1
NTD in Thousand
Main products of New Drugs
Pancreatic cancer
頭頸癌 (Taiwan)
實體腫瘤(製程開發中)
Veregen® 生殖器疣(全球20+國家已上市)
乾式老年黃斑部病變 (US, Taiwan)
Development by SynCoreBio
Ophthalmology
Dermatology
Oncology
Indication Total market value/year
Pancreaticcancer
From Market Research Engine, the global market value of Pancreatic Cancer will increase to
US$13 billion in the year of 2021.
Licensing of New Drug
Market Research Engine Report Id: PPCM417
The New Drug value is growing by the progress as well as licensing negotiation.
Preventive Medicine
10
Domestic Business• Continue to develop new functional food products. In
recent there are 5 products obtaining Health Food certificate and anticipate another one in 2019.
• In the same term there will have another 5 items launching in the market.
International Business• The plant has passed second tier of quality control
system, estimate to apply MUI Halal and sales certificate for abroad in December 2018.
• Getting business opportunities from China, Japan and SEA, in recent there are three food & drug items in preparing to get registration from Malaysia and Indonesia, it will contribute to the revenue in 2019.
Oncology dosages
11
1. Domestic Business:• Solid dosage form is the first plant which had passed TFDA audit in
Taiwan.• Have run pilots of ten products (Breast Cancer, Colorectal Cancer,
Lymphoma, Pancreatic Cancer, Gastric Cancer, Lung Cancer, Ovarian Carcinoma and Leukemia etc).
• Established Oncology dosage department in 2018 to meet instant demand from market.
• Product M(medicine for Gastric Cancer and Colorectal Cancer) is the first BE passed Generic Drug in Taiwan which will launch in 2019.
• Product G (NSCLC) anticipate to launch in Q4 2019.2. International Business:• Product A from OEM is in the registration process in Indonesia,
anticipate can contribute to the revenue in 2019; in the same year there will have another item Product L in registration in Philippine, soonest can contribute to the revenue in 2021.
• PMDA Japan will have a plant audit in November 2018,estimate Product G will obtain license in Q1 2019 and there already have three pharmaceutical companies from Japan are planning to sell.
Sinphar Counter
12
1. Enhance direct services to members:• Walk in to communities, provide services to
public and gaining relationships.• Offer on-time communication and after sell
consulting services.• Create more than 10,000+ members in 2018.2. Sharing medical knowledge to the public:• Organize Health Lectures from North to South
of Taiwan.• Provide field trip to public in the meaning of
understanding manufacturing process of drug, functional food and cosmetic. Numerous visitors have been signed up to visit in 2018 and so does 2019.
• Will expand to become a Tourism Factory for a profound services to members.
Intelligent Manufacturing
13
2016Q1-Q3
2017Q1-Q3
2018Q1-Q3
GroupRevenue(Thousand)
1,540,109 1,565,711 1,617,574
Ave. employee of Group(person)
1,034 1,038 1,012
Ave. revenue per person(Thousand)
1,489 1,509 1,598
1,420
1,440
1,460
1,480
1,500
1,520
1,540
1,560
1,580
1,600
1,620
1,500,000
1,520,000
1,540,000
1,560,000
1,580,000
1,600,000
1,620,000
1,640,000
2016 Q1-Q3 2017 Q1-Q3 2018 Q1-Q3
集團營收
每人營收
From automatic manufacturing, the employee’s ability and caring are both lifting. Now it is considered to implement instant message system and auto-flow system to boost the work.
Employee’s welfare
2017Q1-Q2
2018Q1-Q2
% of growth
Salary(Thousand) 264,000 273,257 3.5%
NTD in Thousand
Natural Resources
14
NTD(Thousand) 2018Q2 2017Q2 2017
Operating Revenue 124,210 101,048 240,723
Net Income 20,948 2,121 37,020Attributable to:
shareholders of the
parent17,200 1,714 30,188
天力科研 Summary
2017
• The published patents and papers:21 patent
applications,1 authorization,11 reviews, 1 international
published, 2 papers published.
2018• Enrich research outcome of Natural Resources.
• Obtained 6 patents and 1~2 papers published.
運動營養Sports Nutrition
(3 international patents)
增強呼吸道健康Boost Respiratory Health
(4 international patents)
提升免疫力,對抗病毒感染
Upregulate Immunity & Against Virus infection(2 international patents)
促進營養吸收Enhance Nutrient
Absorption
(2 international patents)
Target field of Natural Resources
15
Memoregain® TLCT Plus
管花肉蓯蓉提取物(Cistanche tubulosa extracts)
核桃低聚肽(Walnut oligopeptide)
Prodemax™ Lipucan®
茯苓三萜菁萃物(Poria cocos triterpenoids)
The development of Natural Resources
16
1. New Plant:• The second plant of herbal extraction is finished, anticipate can
contribute to revenue in 2019.• New dosage forms are available (aqueous extract, alcohol extract
and enzymatic hydrolysates).2. New Market:• Aim to FMCG market:in the past, food supplement were selling
through drug store, cosmeceutical chain or multi-level companies. Based on the health trend in recent, enter FMCG market as food ingredient can gain more opportunities.
• Enter ASEAN and EU market:ASEAN and EU are two capital markets for Natural Resources, have applied 8 patents through 42 countries.
• Game changer:Natural Product Expo West(Anaheim, USA);CPhI/NEX(Shanghai China) ;Vitafoods Asia (Singapore);Supply Side West (Las Vegas, USA);Hi Europe (Frankfurt, Germany).Bio Taiwan
Group’s Great Health Map
17
Multi-strength of Generic Drugs
The R&D power of New Drug
Strategic plan of Natural Herbal Resources
Recent Events
18
Year 2018
• Sinphar has signed a Technology Transfer cooperation with a Japanese ophthalmological dosage company; in future, ophthalmological dosage will be produced sterilized with special pack for customer-friendly use. This project will launch in Taiwan, Korea and other countries in South East Asia.
• MST(for Gastric Cancer and Colorectal Cancer) is the first BE passed Generic Drug in Taiwan, estimate in 2019 could launch in the market.
• Sinphar has imported an anti-hyperlipidemia product which is in a clinical trial now.
• SynCore Bio becomes general agent in Taiwan of EpiCAM from British company Epipole.
• The develop project SynCore SB05 (EndoTAG®-1)has won the Innovation Prize of 2018 Outstanding Company of the year.
• SynCore Bio SB05 PC gradually passed the application of clinical trial phase III in Taiwan, United States, France, Hungary, Russia, South Korea and Israel.
Year 2017
• Sinphar medicine and Kyowa Chemical Industry Co. ( KISUMA) signed registration contract to exclusively introduce sales of Sinphar counters.
• New drug SB05 (EndoTAG®-1) which developed by SynCore Biotechnology Co., Ltd. had obtained permission by US FDA and TFDA to execute Phase III human clinical trial for pancreatic cancer.
• SynCore Biotechnology SB01 published “A Phase I Dose Escalation Study of SCB01A, a Micro-tubular Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors Refractory to Standard Therapy ” at American Society of Clinical Oncology, ASCO
• SB01 New Chemical Entity, NCE from SynCore Biotechnology for head and neck cancers had obtained R.O.C. patent.
• SB05_EndoTAG-1 from SynCore Biotechnology had obtained manufacturing patent from European patent office and indication patent from United States Patent and Trademark Office.
Corporate Social Responsibility
19
1. Promote social care , medical prevention and health education• Host health forum, biotechnology camp. Combined medical, academia, and biotechnology community to set up an
interaction platform. Also, cultivate talented personnel.
• Continually to sponsor Breast Cancer Foundation, Taiwan Cancer Foundation, Taiwan Alzheimer’s Disease
Association, Spinal Cord Injury Foundation, The Diabetes Association of the Republic of China (Taiwan), Taiwan Yilan
Association of Diabetes Supporters, and Youngsun Culture & Education Foundation.
• 1,300 Sinphar Counters in Taiwan join Taiwan Alzheimer’s Disease Association’s Dementia Friendly Business.
• Donate to The National Health Research Institutes and Formosa Cancer Foundation, to provide subsidy for new drug
development and medical supply.
• Co-found a “ R&D center of Age-related Macular Degeneration” with National Taiwan University Hospital, strive for
the diagnosis of early stage of age-related macular degeneration and eye detection.
• In long term to protect and maintain street lights at Wanshan village, side walk in Zhongshan village and Renshan
trail; also provide a free-use area for trip advisor center in Dongshan County.
2. In long term to support educational activities and sports• Provide internship for students from Kaohsiung Medical University, Taipei Medical University, National Defense
Medical Center, China Medical University and Chia Nan University of Pharmacy & Science. Also provide schloership
for Kaohsiung Medical University and National Defense Medical Center.
• Sponsor musical instruments and international competition found for symphonic band from Dongshan Elementary
School.
• Sponsor World Badminton Athlete, Tai Tzu Ying(戴資穎).
• Team up and anticipate in Yilan Toucheng Township’s and Pingtung Hengchung’s Cianggu (The Grappling with
Ghosts) Competition.
• Sponsor Chinese Taipei Gymnastic Association, National Ilan University gymnastics team, Yilan High school’s
soccer & basketball team and Yilan Chung Dau High School baseball team.
• Sponsor to set up Sinphar Hope Elementary School (China Xinjiang Yutian County).
• Sponsor supplement to Yilan County team in The National Games, donated NT$5 million to Yilan County sport
development found.
Q & A• Business development :Chang, Chih-Chao。 (02-27603688 # 2304)
• Investor Services : Chen, Shu-Hsia。 (02-27603688 # 2237)
top related